课题基金 / 基金详情

项目摘要

项目成果

Stephen Philip Schoenberger的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hematologic cancers pose a unique challenge to the immune system, as they can present their antigens both directly to host T cells, or indirectly following transfer to host ARC, with fundamentally distinct signals accompanying each mode of presentation. For naive CD8+ T cells, the outcome of these events can determine whether an effective anti-tumor response is either induced, or rendered functionally silent through a variety of tolerance mechanisms. There are currently significant gaps in both our understanding of the antigen-presenting cells (APC) capacity of normal B cells or their transformed counterparts, lymphomas and myelomas, as well as the consequences of this for primary antigen-specific CD8+ T cells of in vivo. This application, based on a robust experimental model and supported by strong preliminary data, proposes the hypothesis that under physiological conditions, normal B cells efficiently program a durable state of tolerance in naTve CD8+ T cells through a novel mechanism involving transmission of signals that lead to primary expansion and subsequent uncoupling of the TCR proximal signaling machinery from the downstream cytotoxic effector functions in the clonal progeny. We further suggest that this same pathway is utilized by lymphomas to purge the available CD8+ T cell repertoire of clones capable of recognizing the multitude of antigens that arise during the process of transformation. The objective of this research is therefore to understand how normal and transformed primary B cells induce tolerance in CD8+ T cells under physiological conditions in vivo. Using a novel in vivo transgenic system that features expression of a model antigen on primary B cells, we will pursue the following aims: Aim 1) to characterize of the exact pathways in which B cells induce CD8+ T cell tolerance, Aim 2) to define the molecular defect underlying the tolerant phenotype of CDS T cells, Aim 3) to determine whether spontaneous lymphomas induce CD8+ T cell tolerance via the same pathway, and Aim 4) to establish methods through which the induction of CDS T cell tolerance by B cells can be prevented or overcome. The results of these studies will shed important new light on the APC function of normal and transformed B cells, and will allow the development of much-needed new strategies for enhancement of immune responses to B cell tumors.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1201685
发表时间: 2013-01-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Feau S, Schoenberger SP, Altman A, Bécart S]
通讯作者: Bécart S
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer
  • 批准号:
    10718057
  • 项目类别:
  • 资助金额:
    $62.92万
  • 财政年份:
    2023
  • 负责人:
    Stephen Philip Schoenberger
  • 依托单位:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
  • 批准号:
    8990833
  • 项目类别:
  • 资助金额:
    $19.25万
  • 财政年份:
    2014
  • 负责人:
    Stephen Philip Schoenberger
  • 依托单位:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
  • 批准号:
    8810185
  • 项目类别:
  • 资助金额:
    $23.1万
  • 财政年份:
    2014
  • 负责人:
    Stephen Philip Schoenberger
  • 依托单位:
Cellular and Molecular Regulation of CD8+ T cell memory
  • 批准号:
    8563544
  • 项目类别:
  • 资助金额:
    $41.6万
  • 财政年份:
    2013
  • 负责人:
    Stephen Philip Schoenberger
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究